HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
N- 7- (2- (nitrophenyldithio)ethyl)mitomycin C
better antitumor activity than mitomycin C
Also Known As:
BMS 181174; BMS-181174; BMY 25067; BMY-25067
Networked:
14
relevant articles (
1
outcomes,
7
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Quinones: 434
Indolequinones: 12
Mitomycins: 11
N-7-(2-(nitrophenyldithio)ethyl)mitomycin C: 14
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azirines
Mitomycins: 11
N-7-(2-(nitrophenyldithio)ethyl)mitomycin C: 14
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Indoles: 200
Indolequinones: 12
Mitomycins: 11
N-7-(2-(nitrophenyldithio)ethyl)mitomycin C: 14
Related Diseases
1.
Neoplasms (Cancer)
04/01/1996 - "
Combinations of low doses of BMS-181174 plus a large dose of radiation were very effective in killing cells in solid tumors.
"
04/01/1996 - "
In vivo, BMS-181174 was effective in killing cells in solid EMT6 tumors.
"
10/01/1999 - "
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.
"
04/01/1996 - "
Interactions of BMS-181174 and radiation: studies with EMT6 cells in vitro and in solid tumors.
"
04/01/1996 - "
However, the survival curve plateaued at high doses of BMS-181174, providing evidence for a subpopulation of tumor cells which were resistant to both BMS-181174 and radiation; this was hypothesized to be a hypoxic cell population.
"
2.
Urinary Bladder Neoplasms (Bladder Cancer)
08/01/1996 - "
The present study was undertaken to determine the role of GSH in cellular activation of BMS-181174 using a pair of well-characterized human bladder cancer cells (J82 and SCaBER) as a model.
"
01/01/1997 - "
This study was undertaken to elucidate the mechanism of cellular resistance to BMS-181174, a novel analogue of mitomycin C (MMC), in a human bladder cancer cell line.
"
08/16/1995 - "
This study describes characteristics of a human bladder cancer cell line, SCaBER/R, selected for resistance to a mitomycin C (MMC) analogue BMY 25067.
"
02/01/1994 - "
This study was undertaken to elucidate the mechanism(s) of differential sensitivity of human bladder cancer cell lines J82 and SCaBER to mitomycin C (MMC) and its analogue, BMY 25067.
"
08/16/1995 - "
Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C.
"
3.
Thrombophlebitis
06/01/1998 - "
BMS-181174 has anti-cancer activity but, because of its toxicity, particularly pneumonitis and thrombophlebitis, no phase II studies are planned.
"
4.
Pneumonia (Pneumonitis)
06/01/1998 - "
BMS-181174 has anti-cancer activity but, because of its toxicity, particularly pneumonitis and thrombophlebitis, no phase II studies are planned.
"
5.
Cardiotoxicity
07/01/1989 - "
The potential cardiotoxicity, nephrotoxicity, and pulmonary toxicity of several mitomycin (MMC) derivatives, BMY-25067 (N-7-[2-(4-nitrophenyldithio)ethyl]MMC), BMY-26107 (N-7-[2-(4-aminophenyldithio)ethyl]MMC), BMY-26605 (N-7 acetyl-MMC), BMY-25690 (7-N-(dimethylaminomethylene)-10-[1-morpholinomethyleneamino)carbo nyl- oxy]MMC), BMY-26646 (N-7-[2-(4-fluorophenyldithio)ethyl]MCC), and BMY-25551 (7-(2-hydroxyethyl)mitosane), were evaluated in rats.
"
Related Drugs and Biologics
1.
Mitomycin (Mitomycin-C)
2.
DNA (Deoxyribonucleic Acid)
3.
N(6)-((dimethylamino)methylene)mitomycin C
4.
Porfiromycin
5.
Glutathione (Reduced Glutathione)
6.
Free Radicals
7.
Doxorubicin (Adriamycin)
8.
Ribosomal DNA (rDNA)
9.
Dicumarol (Dicoumarol)
10.
Antineoplastic Agents (Antineoplastics)
Related Therapies and Procedures
1.
Intravenous Injections
2.
Therapeutics
3.
Radiotherapy